Vandebroek Sophie V.

SEC source: 0001567619-20-009380 · doc1.xml · derivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,741

Underlying: Common Stock · 370 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-20-004494 · doc1.xml · derivative · entry 7

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,902 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable on May 4, 2017.

SEC source: 0001567619-20-004494 · doc1.xml · derivative · entry 6

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,666 shares

Expires 2025-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 4, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-004494 · doc1.xml · nonDerivative · entry 4

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,321

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $286.86 to a high of $287.05 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-004494 · doc1.xml · nonDerivative · entry 3

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-004494 · doc1.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,321

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $286.86 to a high of $287.05 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-004494 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-001950 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,321

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-020254 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,251

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-017053 · doc1.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Sophie Vandebroek Revocable Trust

Disclosed balance after: 6,000

F1 · ownership.nature: The shares are held by the Sophie Vandebroek Revocable Trust datedd June 28, 2019, of which the Reporting person is grantor, a trustee and a beneficiary.

SEC source: 0001567619-19-017053 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,178

SEC source: 0001567619-19-015984 · doc1.xml · derivative · entry 6

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,666

Underlying: Common Stock · 6,056 shares

Expires 2025-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 4, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015984 · doc1.xml · derivative · entry 5

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,988 shares

Expires 2024-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 4

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,178

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 3

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,178

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,116

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015623 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,178

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-010456 · doc1.xml · derivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010456 · doc1.xml · derivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,371

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-009682 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,108

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-002179 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,027

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-18-004943 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,937

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-18-035892 · doc1.xml · derivative · entry 6

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,988

Underlying: Common Stock · 2,986 shares

Expires 2024-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-18-035892 · doc1.xml · derivative · entry 5

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,952 shares

Expires 2023-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,476 shares on May 7, 2014, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-18-035892 · doc1.xml · nonDerivative · entry 4

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,848

SEC source: 0001140361-18-035892 · doc1.xml · nonDerivative · entry 3

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-035892 · doc1.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,612

SEC source: 0001140361-18-035892 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-034856 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,175

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-18-023104 · doc1.xml · derivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,187

Underlying: Common Stock · 2,187 shares

Expires 2028-05-08

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001140361-18-023104 · doc1.xml · derivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,944

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001140361-18-021322 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,096

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-17-018661 · doc1.xml · derivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,046

Underlying: Common Stock · 3,046 shares

Expires 2027-05-02

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018.

SEC source: 0001140361-17-018661 · doc1.xml · derivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,720

Underlying: Common Stock · 289 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.